Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation
- PMID: 17584768
- DOI: 10.1093/hmg/ddm151
Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation
Abstract
Pathogenic mutations in the leucine-rich repeat kinase-2 (LRRK2) gene cause autosomal-dominant and certain cases of sporadic Parkinson's disease (PD). The G2019S substitution in LRRK2 is the most common genetic determinant of PD identified so far, and maps to a specific region of the kinase domain called the activation segment. Here, we show that autophosphorylation of LRRK2 is an intermolecular reaction and targets two residues within the activation segment. The prominent pathogenic G2019S mutation in LRRK2 results in altered autophosphorylation, and increased autophosphorylation and substrate phosphorylation, through a process that seems to involve reorganization of the activation segment. Our results suggest a molecular mechanistic explanation for how the G2019S mutation enhances the catalytic activity of LRRK2, thereby leading to pathogenicity. These findings have important implications for therapeutic strategies in PD.
Similar articles
-
A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.Eur J Neurol. 2007 Apr;14(4):413-7. doi: 10.1111/j.1468-1331.2007.01685.x. Eur J Neurol. 2007. PMID: 17388990
-
MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease.J Neurosci Res. 2007 May 1;85(6):1288-94. doi: 10.1002/jnr.21240. J Neurosci Res. 2007. PMID: 17385669
-
Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.Neurobiol Dis. 2015 May;77:49-61. doi: 10.1016/j.nbd.2015.02.019. Epub 2015 Feb 28. Neurobiol Dis. 2015. PMID: 25731749
-
LRRK2 in Parkinson's disease: genetic and clinical studies from patients.FEBS J. 2009 Nov;276(22):6455-63. doi: 10.1111/j.1742-4658.2009.07344.x. Epub 2009 Oct 5. FEBS J. 2009. PMID: 19804413 Review.
-
Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.Biochem Soc Trans. 2012 Oct;40(5):1058-62. doi: 10.1042/BST20120054. Biochem Soc Trans. 2012. PMID: 22988865 Review.
Cited by
-
LRRK2 regulates retrograde synaptic compensation at the Drosophila neuromuscular junction.Nat Commun. 2016 Jul 19;7:12188. doi: 10.1038/ncomms12188. Nat Commun. 2016. PMID: 27432119 Free PMC article.
-
Non-cell autonomous mechanism of Parkinson's disease pathology caused by G2019S LRRK2 mutation in Ashkenazi Jewish patient: Single cell analysis.Brain Res. 2019 Nov 1;1722:146342. doi: 10.1016/j.brainres.2019.146342. Epub 2019 Jul 19. Brain Res. 2019. PMID: 31330122 Free PMC article. Review.
-
The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites.Biochem Biophys Res Commun. 2009 Nov 20;389(3):449-54. doi: 10.1016/j.bbrc.2009.08.163. Epub 2009 Sep 3. Biochem Biophys Res Commun. 2009. PMID: 19733152 Free PMC article.
-
Combined kinase inhibition modulates parkin inactivation.Hum Mol Genet. 2009 Mar 1;18(5):809-23. doi: 10.1093/hmg/ddn407. Epub 2008 Dec 2. Hum Mol Genet. 2009. PMID: 19050041 Free PMC article.
-
Structural and functional in silico analysis of LRRK2 missense substitutions.Mol Biol Rep. 2014;41(4):2529-42. doi: 10.1007/s11033-014-3111-z. Epub 2014 Feb 2. Mol Biol Rep. 2014. PMID: 24488318
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical